Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Blood markers may reveal why some women get repeat UTIs

NCT ID NCT03819712

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 2 times

Summary

This study aims to find blood biomarkers that predict recurrent urinary tract infections (UTIs) in women. Researchers will collect blood, urine, fecal, and vaginal samples from 109 healthy women aged 18–28, comparing those with a history of single versus recurrent cystitis. The goal is to understand how immune system differences may raise the risk of repeat infections, potentially leading to better prevention strategies.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

What this could lead to
If successful, this could help identify women at high risk for recurrent UTIs and guide future research into better prevention or treatment.
What could go wrong
This is an observational study, not a treatment trial. It is small (109 participants) and only looks at biomarkers, so it won't directly change care.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

109 people

The number who actually took part.

Started

Jun 2019

Expected to finish

Dec 2025

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 28 years

Sex

Female participants only

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Female aged 18 to 28 years; * Subject accepting to be serologically tested for HIV and HCV; * Subject considered healthy by the physician on the basis of medical history and clinical examination; * Subject with a body mass index between 18.5 and 30 kg/m2; * Subject understands and speaks French and is able to give written consent; * Subject affiliated to Social Security or a similar regime; * Having reported a single cystitis since the age of 14 (Group 1), or 3 or more cystitis over a 12-month period since the age of 14 (Group 2). Exclusion Criteria: * Subject protected by law under guardianship or curatorship, or unable to participate in a clinical study under Article L. 1121-16 of the French Public Health Code; * Subject who has participated in a clinical research study in the last 3 months in which he/she was exposed to a pharmaceutical product or medical device; * Subject who has stayed in a tropical or subtropical country in the last 3 months; * Pregnant or breastfeeding subject for women of childbearing age; * Subject with special diet for medical reasons and prescribed by a doctor or dietician (e.g. a low-calorie diet or a diet intended to lower cholesterol levels); * Subject who regularly consumes large quantities of alcohol, i. e. more than 50 g of pure alcohol per day (e. g. more than 4 glasses of 150 ml wine, more than 4 pints of 250 ml beer, or more than 4 glasses of 40 ml containing strong alcohol); * Subject who has used an illegal recreational drug in the past 3 months; * Subject who has taken an immunosuppressive or immunomodulatory drug (excluding intranasally or topically administered corticosteroids) in the past 2 weeks, or for more than 14 consecutive days in the past 6 months; * Subject who has been vaccinated within the last 3 months; * Subject who received a blood transfusion or immunoglobulins in the last 3 months; * Subject stating that he has not been fasting for at least 10 hours; * Subject reporting HIV or HCV status; * Subject who had an infectious episode or was treated with antibiotics during the 4 weeks prior to the visit; * Subject with a positive urinary pregnancy test; * Subject with a severe and/or chronic and/or recurrent pathology, in particular: * A chronic inflammatory and/or autoimmune or allergic disease and in particular a chronic inflammatory disease of the intestine (Crohn's disease, ulcerative colitis), epidermis (psoriasis, atopic dermatitis), joints (rheumatoid arthritis), nervous system (multiple sclerosis), type I diabetes; * High blood pressure or type II diabetes; * A neurodegenerative disease. * Subject who has been diagnosed with cancer and has not been in remission for more than 5 years.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Urinary tract infections are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • Hôpital de l'Archet 1 - CHU de Nice - Service d'Infectiologie

    Nice, 06200, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.